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The ability of modular protein domains to independently fold and bind short peptide ligands both
in vivo and in vitro has allowed a signiﬁcant number of protein–protein interaction studies to take
advantage of them as afﬁnity and detection reagents. Here, we refer to modular domain based pro-
teomics as ‘‘domainomics’’ to draw attention to the potential of using domains and their motifs as
tools in proteomics. In this review we describe core concepts of domainomics, established and
emerging technologies, and recent studies by functional category. Accumulation of domain–motif
binding data should ultimately provide the foundation for domain-speciﬁc interactomes, which will
likely reveal the underlying substructure of protein networks as well as the selectivity and plasticity
of signal transduction.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction family recognizing motifs with similar characteristics, such asEukaryotic proteins are modular in nature. Many proteins con-
tain independently folding globular domains capable of binding
short peptide motifs even when both domain and motif are re-
moved from the context of their full-length protein [1,2]. Modular
protein interacting domains facilitate protein–protein interactions
required for a diverse set of cellular processes including signal
transduction and subcellular localization. Domains are categorized
based on structural and sequence homology, with each domainchemical Societies. Published by E
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chida).phosphorylated tyrosine (pTyr) or proline rich sequences (Table 1).
The combination of modular domains within a protein contributes
to its biological function by deﬁning its protein interaction net-
work. The post-translational modiﬁcation (PTM) of amino acid side
chains within a peptide motif can modulate domain–motif binding,
providing the basis for the elegant and complicated protein signal-
ing networks required for life [3]. Over the past decade, exploita-
tion of a number of high-throughput proteomic technologies
including increasingly sensitive mass spectrometry (MS) and pro-
tein microarrays has led to the dissection of vast protein interac-
tion networks and the role of PTMs in altering network topology
[4]. Accurate quantiﬁcation of protein–protein interactions and
PTM is now possible [5].
Because of the role of modular domains in assembling protein
complexes, a signiﬁcant portion of proteomics studies take advan-
tage of modular domains as a means to assess protein–protein
interactions (e.g., as bait in pull-down or probes in microarray).
Here we refer to this modular domain-based proteomics as
‘‘domainomics.’’ While this may be a somewhat artiﬁcial segmen-
tation, it is meant to draw attention to the potential of domains
and their motifs as tools in contemporary proteomics. The emer-
gence of domainomics as a unique sub-genre of proteomics raises
a number of important questions: (1) What are the characteristics
of modular domains as a research tool? (2) How are assays tailored
to address speciﬁc scientiﬁc questions? (3) What technologies are
available for exploiting domains as tools? (4) What lessons can belsevier B.V. All rights reserved.
Table 1
Characteristics of modular binding domains. Representative modular protein domains grouped by functional categories are presented. Approximate amino
acid sizes (a.a) and afﬁnity ranges are based on our literature search. The number of human domains and domain-containing proteins were estimated using
the SMART database.
Recognition Name Size (a.a) Domain Protein Afﬁnity
Phosphotyrosine PTB 100–150 36 31 nM–lM
SH2 100 120 110 nM–lM
PTPa 250–280 50 38 nM–lM
Phosphoserine & phosphothreonine 14-3-3 250 8 8 nM–lM
BRCT 90–100 46 24 nM–lM
FF 50–60 25 6 nM–lM
FHA 65–100 31 31 nM–lM
MH2/DWB 200 8 8 nM–lM
POLO-Box 200 5 5 nM–lM
Polyproline EVH1/WH1 115 8 8 lM
GYF 60 3 3 lM
SH3 60 291 217 nM–lM
WWb 38–40 88 48 lM
Methyllysine LRR 22–28 1967 228 lM
PHD 50 168 96 lM
Chromo 30–70 43 31 lM
MBT 100 29 9 lM
Tudor 50 55 27 lM
PWWP 135 17 14 lM
Acetyllysine BROMO 110 64 46 lM
C-Terminus PDZ 90 264 151 nM–lM
Miscellaneous: (b-propeller family) WD40c 40–60 1682 272 nM–lM
a Catalytic domains of protein tyrosine phosphatases (PTP) are included because of their potential use in domainomics.
b Pin 1 WW domain can bind phosphoserine and threonine motifs.
c Typically seven WD40 repeats form a b-propeller module. These modules have been reported to recognize various ligand modiﬁcations including
serine-phosphorylated, threonine-phosphorylated, lysine-methylated, and ubiquitinated residues.
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diction become a reliable tool? (6) What insights can domainomics
provide for the protein interactome? Providing comprehensive an-
swers to all these questions would be a challenging task for any
single review. However, we believe an overview of domainomics
will provide some insight into these topics. We ﬁrst describe the
core concept of domainomics, then outline established and emerg-
ing technologies, and review recent studies by functional category.
We ﬁnish with a perspective on the unique potential of domainom-
ics and a discussion of how to enhance its role in proteomic
studies.
2. Modular protein interacting domain as afﬁnity reagents
Independent folding of domains, which preserves binding capa-
bilities, allows for their use as afﬁnity and detection reagents in a
manner similar to antibodies. For example, in Western blotting,
protein expression is visualized by probing a membrane-bound
denatured lysate with a speciﬁc antibody. Similarly, a labeled do-
main probe is used to detect the presence of domain binding sites
in far-Western blotting [6]. As an afﬁnity reagent, an immobilized
antibody can be incubated with a lysate to enrich for the target
protein and its interacting partners (immunoprecipitation). Do-
mains can also be used to pull-down binding partners within a ly-
sate for identiﬁcation by MS [7]. However, the functional
characteristics of antibodies and domains differ in many ways.
Antibodies are biochemically homogeneous, therefore procedures
required in proteomics, such as puriﬁcation, modiﬁcation for label-
ing, and immobilization, can be shared. In contrast, each modular
domain is a part of a different full-length protein, and as such,
has distinct biochemical properties such as solubility and struc-
tural stability [8]. Thus, experimental procedures must be tailored
to take advantage of each domain’s physiological binding activity.
Further, the speciﬁcity spectrum of antibodies and domains is
qualitatively different. Antibodies are meant to recognize an epi-
tope on target molecules; so off target cross-reactivity can badly
affect quantitative results. Therefore, multiple validation and nor-malization steps are necessary to eliminate false positive signals
in antibody-based proteomics [9,10]. On the other hand, modular
domains naturally have wide-ranging speciﬁcity; promiscuity in li-
gand selection is considered a physiological propensity rather than
experimental noise. Taken together, modular domains and anti-
bodies both can serve as useful afﬁnity reagents in biochemical re-
search, though procedures and research applications are often
quite different.
3. Application design
As afﬁnity and detection reagents, modular domains and their
short peptide ligands (motifs) can be used in three basic proteomic
designs: motif scanning (motifs are scanned), domain scanning
(domains are scanned), and multiplex scanning, each differing in
their concept and execution (Fig. 1). ‘‘Motif scanning’’ surveys pos-
sible interaction partners containing a binding motif for a modular
domain of interest. Typically, a modular domain is used as an afﬁn-
ity probe to either a library of synthesized peptides (e.g., SPOT ar-
rays) or a whole proteome (e.g., far-Western and pull-down
experiments). Motif scanning has been frequently used to deﬁne
binding consensus motifs [11–13], to determine binding sites
[14,15], and to identify interacting proteins within a particular cel-
lular environment, such as during growth factor treatment [7,16].
In addition, a labeled domain can be used as a quantitative proﬁl-
ing tool for determining the presence or absence of modular do-
main binding sites in a group of cancer cell lysates or tissues [17].
‘‘Domain scanning’’ uses a peptide binding motif as bait to
screen a library of domains (e.g., domain microarray) or a prote-
ome (e.g., pull-down experiments). This approach is often used to
determine binding partners when a putative domain binding motif
is known to play an important role. For example, downstream
effector docking sites are often examined using domain scanning
[18,19].
In ‘‘multiplex scanning,’’ binary interactions between many do-
mains and motifs are simultaneously analyzed in the same exper-
imental system. By determining interactions between nearly all
Fig. 1. Domainomics assay designs. The three basic assay designs for studying
interactions between modular protein domains and short peptide motifs are
depicted. Top: in motif scanning, a domain of interest is used to probe a library of
peptide motifs or proteins containing binding motifs, typically to deﬁne domain
speciﬁcity or identify possible binding proteins. For example, an immobilized
domain can be used as bait in pull-downs. Middle: in domain scanning, a motif of
interest is used as a probe to screen a set of domains or domain-containing proteins.
Bottom: multiplex scanning simultaneously assesses interactions between many
ligands and domains, providing the speciﬁcities of domains within a domain–motif
interaction map. Multiplex scanning can be designed as an expanded version of
domain or motif scanning, or as a ‘‘library to library pull-down’’ to screen for
binding modules (see Section 5.3).
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peptide motifs in equivalent assay conditions, multiplex scanning
allows for construction of domain interaction maps or classiﬁca-
tion of domain speciﬁcity [2,20,21].
Assays can be multiplexed by expanding the experimental
scale of either motif scanning or domain scanning. For example,
simultaneous analysis of 61 peptides and 159 domains using a
microarrays-in-microplates system has been conducted [22].
Alternatively, use of one tube multiplex assays, in which multi-
ple domains compete in binding, have also been reported [23–
25].
In addition to these different designs, binding assays can be cat-
egorized as ‘‘in vivo or in vitro’’ and ‘‘direct or indirect.’’ Domain–
motif interactions detected in vitro should be conﬁrmed by
in vivo methods, such as co-immunoprecipitation or in vivo pull-
downs. Interactions observed in lysate-free systems, e.g., peptide
arrays, and far-Westerns are considered direct, while immunopre-
cipitation or pull-downmay detect direct, and indirect interactions
due to bridging across precipitated proteins (e.g., Fig. 2E). Here, the
presence of a known binding site for the bait within an identiﬁed
protein suggests direct binding. In either case, direct binding
should be conﬁrmed using orthogonal assay systems. Importantly,
indirect binding does not necessarily mean such an interaction is
not speciﬁc; rather, it may represent an important functional sub-
cellular complex [26].4. Domain-based proteomics assays
In this section we brieﬂy describe core technologies for domai-
nomics, namely, in silico screening, forward- and reverse-phase ar-
rays, phage display, bead array, and photocrosslinking, as well as
other methods (Fig. 2).4.1. In silico screen
A number of searchable databases are available to obtain se-
quences, domain structures, PTM sites, and known interactions
including NCBI gene, Human Protein Reference Database (HPRD),
SMART, Pawson lab website, PROSITE, Domino, Phospho.ELM,
PhosphoSitePlus, MnM, and PhosphoNET. Prior to either ‘‘domain
scanning’’ or ‘‘motif scanning’’ studies (Fig. 1), it is advisable to
use web-based prediction tools to test potential domain–motif
interactions, possibly eliminating unnecessary experiments and
helping efﬁcient experimental design [27]. Prediction tools include
Scansite, NetPhorest, SMALI, and DomPep [28–30]. Prediction
models are typically based around position speciﬁc scoring matri-
ces (PSSMs), which are trained using a set of experimentally deter-
mined interactions. Based on the training set, PSSMs deﬁne the
likelihood of observing a particular amino acid at a speciﬁc posi-
tion within a peptide that is known to bind a domain [2,21]. Using
this information, peptide binding scores can be calculated and used
to predict the likelihood of novel peptide binding. However, the
predictive ability of PSSM-based models may be limited by interac-
tion training sets that are insufﬁcient to deﬁne every position with-
in the matrix, the lack of sufﬁcient negative interaction training
data, and their inability to incorporate the effect of residue interde-
pendence on peptide binding [31–33].
4.2. Forward phase array
Analogous to antibody microarrays, modular binding domains
can be immobilized on a solid surface and probed with
ﬂuorophore/enzyme-labeled peptides or proteins (Fig. 2A) [2].
The labeling can be direct, or indirect via a biotin-streptavidin or
epitope-tag system [34,35]. Fluorescence-based detection systems
are more amenable to quantitative analysis, while enzymatic
detection may provide signal ampliﬁcation [36]. Labels should be
sufﬁciently spaced from motifs to minimize steric hindrance in li-
gand binding [37,38]. However, a major concern for the forward
phase format is whether immobilization of recombinant domain
proteins might disrupt the conformation and orientation required
for ligand binding [39–41]. For instance, covalent binding provides
strong association to solid surfaces, but the modiﬁcation of chem-
ical groups which occurs could interfere with domain binding to
speciﬁc ligands. Thus, the immobilization method for a given
domain must be carefully optimized with an appropriate evalua-
tion method that incorporates modular domain-speciﬁc positive
and negative controls, e.g., modiﬁed and unmodiﬁed peptides,
and wild type and mutated domains. Currently domain arrays
are mainly used to survey synthetic peptides or puriﬁed proteins.
A prototypic domain array containing SH2, SH3, WW, PDZ, 14-
3-3, FHA, PH, and EF domains on a nitrocellulose coated glass slide
was introduced by Espejo et al. in 2002 [34]. In this assay, activity
of immobilized SH3 domains was conﬁrmed with peptides con-
taining known SH3 motifs. In addition, they showed that endoge-
nous proteins in cell lysates were bound by SH3 domains and
could be detected using speciﬁc antibodies. Polyacrylamide hydro
gel pads have also been used for protein domain immobilization
[42]. Macbeath’s group introduced a multiplex forward phase
microarray by spotting the full complement of human SH2/PTB do-
mains onto aldehyde-modiﬁed glass [22]. This system enabled
Fig. 2. Domainomics technologies. (A) Forward phase array. Modular domains are immobilized on a solid support and probed with a peptide motif or protein (domain
scanning). Duplicate arrays can be probed with different peptides (multiplex scanning). Binding is detected through a peptide-conjugated tag using ﬂuorescence- or enzyme-
based systems. (B) Reverse phase array. Peptides or proteins are immobilized on a solid support and probed with a tagged domain (motif scanning). Duplicate arrays can be
probed with different domains (multiplex scanning). Binding is detected through a domain-conjugated tag using ﬂuorescence- or enzyme-based systems. (C) Phage display.
Peptide libraries are expressed as bacteriophage coat protein fusions and incubated with an immobilized domain (motif scanning). High afﬁnity ligands are identiﬁed by
sequencing of phage DNA. Multiple domains can be studied in separate wells with replicate libraries (multiplex scanning). Domains expressed on the phage surface can also
be incubated with an immobilized peptide or protein (domain scanning). (D) Bead array. A bead-bound peptide library is probed with a tagged domain (motif scanning).
Duplicate arrays can be probed with different domains (multiplex scanning). Binding is detected through a conjugated tag using ﬂuorescence-, enzyme-, or mechanical-based
systems. Peptide sequences are identiﬁed via mass spectrometry. Domains can also be immobilized on beads and probed with a motif (domain scanning). (E) In vivo
photocrosslinking. This approach allows for incorporation of a photocrosslinking amino acid, e.g., p-benzoyl-L-phenylalanine (pBpa) into a modular domain expressed in vivo.
Bound ligands are crosslinked to the domain under UV light, subjected to a pull-down assay using an afﬁnity tag, and identiﬁed by MS. Covalent binding between the domain
and ligands improves identiﬁcation of weak transient binders, and allows for removal of indirect binding proteins by rigorous washing steps.
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dependence of binding on ligand concentration, providing a more
reliable measure than results obtained from a single ligand
concentration.
4.3. Reverse phase array
In proteomics, reverse phase arrays are represented by lysate
microarrays in which a large number of samples immobilized on
a chip are probed with a speciﬁc antibody. Similarly, epitope-
tagged or labeled domains can be used to probe a microarray or
macroarray on which peptides, proteins, or lysates are immobi-
lized (Fig. 2B). As opposed to forward phase domain arrays, there
is little concern associated with immobilization process as do-
mains remain in solution. However, binding afﬁnity may be af-
fected by the type of labeling or epitope-tag used. Reverse phase
arrays are particularly suitable to screen large-scale libraries of
peptide motifs to determine consensus sequences for domains
[43,44]. Liu et al. performed a SPOT based array analysis, probing
a set of 192 phosphotyrosine peptides with 50 SH2 domains. They
found that the selectivity of SH2 domains is driven not only by per-
missive (favorable) amino acid motifs but also non-permissive
neighboring residues [45]. Our lab has generated a multiplex re-
verse phase array system in which a group of sample spots are
probed with many SH2 domains in register within a 96-well plate
apparatus, allowing for the assessment of 2000 domain–motif
interactions in a single plate [8].4.4. Phage display
Phage display provides a renewable and scalable source of pep-
tides or domains for proteomics screens using conventional tools
available to most labs [46]. In this assay, foreign DNA fragments
are expressed as fusions with coat proteins on the surface of the
bacteria phage (Fig. 2C). Typically, 5–45 amino acid peptides are
expressed as N-terminal fusions, however C-terminal fusions are
also technically possible [47]. A process known as biopanning iso-
lates high afﬁnity clones through repetitive binding, washing, elut-
ing and ampliﬁcation [48]. High afﬁnity clones are identiﬁed by
sequencing of phage DNA and used to deﬁne the speciﬁcity of do-
main binding and natural domain ligands. Using this technology,
large-scale multiplex scanning has been performed [49,50]. For
example, 1010 randomized peptides motifs were screened against
145 domains [21]. While phage display is typically used to express
peptide motifs, Saksela’s group expressed a full complement of SH3
domains on the phage surface. Using this phage library, they re-
vealed that some SH3 domains can bind ligands with nanomolar
afﬁnity, a much higher afﬁnity than previously reported [51]. This
library is now publicly available and widely used for domain scan-
ning [52,53].
4.5. Bead array
Bead-based assays have been used successfully for motif scan-
ning of multiple domain families including PHD, SH2 and PTB do-
2590 J.A. Jadwin et al. / FEBS Letters 586 (2012) 2586–2596mains [13,54,55]. These arrays provide an easy, cost-effective com-
plement to microarrays. In bead-based assays, a large number of
pooled peptides can be screened simultaneously without the need
for prior spatial separation of peptides [56]. Typically, combinato-
rial peptide libraries are synthesized on beads and probed with
epitope-tagged modular domains (Fig. 2D). Interactions are de-
tected using various methods such as ‘‘on bead western’’, FACS,
or magnetic nanoparticle pull-down; peptides are then identiﬁed
by MS [13,56,57]. Generally, bead-based binding assays do not ex-
cel at quantiﬁcation; as this requires a secondary assay in an
orthogonal format using resynthesized peptides. To circumvent
this, Astle et al. developed a bead-to-microarray screen. Peptides
with positive interactions are cleaved from beads, divided into
two fractions. One fraction is spotted on microarray for quantiﬁca-
tion by domain titration, and the other is used for sequence iden-
tiﬁcation. By virtue of throughput and quantiﬁcation capability,
this system is thought to be suitable for screening of domain–pep-
tide inhibitors [56].
4.6. In vivo photocrosslinking
In vitro substitution of a speciﬁc amino acid residue within a
protein with an unnatural amino acid by manipulation of the ribo-
somal machinery was ﬁrst described in late 80s [58,59]. Decades
later, using bacterial amber suppressor tRNA and aminoacyl-tRNA
synthetase speciﬁc for an unnatural amino acid, it is now possible
to express mutated proteins containing unnatural residues harbor-
ing speciﬁc functional side chains in mammalian cells [60–62].
Incorporation of photo-reactive cross-linking amino acids such
as p-benzoyl-L-phenylalanine (pBpa) into a modular domain of
interest is particularly promising when studying transient do-
main–motif interactions (Fig. 2E) [63]. It allows for the capture of
domain binding proteins whose interactions may not survive
extensive washing during immunoprecipitation. Using this
scheme, a photo-reactive domain and its ligands are cross-linked
using UV-illumination, immunoprecipitated using an afﬁnity tag,
and subjected to LC–MS/MS. Recently, photocrosslinking methods
were used to study in vitro SH2 or SH3 domain interactions
[64,65]. These studies led to the discovery of previously unidenti-
ﬁed substrates. This approach is suitable for motif scanning by
trapping proteome-wide interactors in vivo. However, a potential
weakness of this technology is that mutation sites and cross-linker
side-chain moieties may interfere with physiological ligand inter-
actions [64]. The mutation site should be carefully determined so
that the cross-linking site is close enough to the binding surface
without causing steric interruption of ligand binding [65]. Because
of the availability of a range of unnatural amino acids with various
chemical functionalities and their potential capabilities in studying
PTM-dependent protein–protein interactions in real time in vivo,
studies using these technologies will clearly beneﬁt domainomics
[66]. For example, incorporation of a metabolically stable analog
of phosphotyrosine could serve as a new tool in pTyr-interacting
domain screening [67].
4.7. Other technologies
The yeast two-hybrid system (Y2H) has been an useful method
for identifying novel domain interactions [68–70]. Modiﬁed Y2H
assays provide a method for screening PTM-dependent interac-
tions [71,72]. However, some Y2H screens have high false positive
and negative rates [73]. ELISA-based systems have also been used
in domainomics [74,75]. Fluorescent polarization has proven to be
an useful method, capable of real-time in solution kinetic measure-
ments, for drug screens or validation of microarray data [2,76].
Alphascreen, a commercially available bead-based proximity as-
say, also shows promise as a sensitive tool for assessment of do-main–motif interactions and drug discovery [77]. In this assay, a
pair of proteins are indirectly labeled with either donor or acceptor
microbeads. If the proteins are interacting, irradiation of a donor
bead triggers activation of a nearby acceptor bead, amplifying
the chemiluminescence signal, which provides greater sensitivity
and dynamic range [78,79]. Proximity ligation assay is becoming
a popular tool due to its high sensitivity and speciﬁcity in analyz-
ing protein–protein interactions [80]. Commonly this approach is
used in situ where cells or tissues are ﬁxed and incubated with a
pair of oligonucleotide-labeled antibodies for two proteins that
are hypothesized to interact. Interactions are detected via rolling
circle ampliﬁcation [81]. An in-solution proximity ligation assay
has also been reported as a multiplex protein detection tool requir-
ing only 1 ll per sample [82].5. Survey of domainomics
In this section we focus on representative domains in functional
categories, how they are used in domainomics studies and what
lessons can be learned from these applications.
5.1. Phosphotyrosine recognizing domains
At this time, there are 3370 experimentally veriﬁed tyrosine
phosphorylation sites in eukaryotic proteins according to Phos-
pho.ELM [83]. The majority of pTyr-binding proteins contain SH2
domains, PTB domains, or both (Table 1) [84,85]. SH2 domains are
approximately 100 amino acids in length and bind in a pTyr speciﬁc
manner via a conserved binding pocket [12,86,87]. PTB domains are
100–150 residues long, are found in scaffold proteins such as Shc
and IRS-1, and vary in their dependence on phosphorylation [88].
Several other pTyr binding modules, such as the PKC delta C2 do-
main and pyruvate kinase M2, have also been reported [15,89].
pTyr-dependent reversible interactions are crucial in propagat-
ing signals from activated receptor tyrosine kinases to downstream
effectors. For example, upon stimulation, ErbB/EGF receptors auto-
phosphorylate multiple Tyr sites on their cytoplasmic tails that
serve as docking sites for SH2/PTB containing downstream effec-
tors [90,91]. To focus our methodological discussion, we outline
independent domainomics studies on ErbB family receptors. Bla-
goev et al. used the Grb2-SH2 domain as bait to pull-down the
EGFR interactome in HeLa cells [7]. They employed the SILAC
method to quantify EGF-dependent interactions. Their study iden-
tiﬁed 228 proteins, of which 28 proteins, including 6 SH2 proteins
and the novel interactor CD59, were selectively enriched upon
stimulation. Schulze et al. conducted a SILAC pull-down with
pTyr–peptide bait corresponding to all 89 ErbB cytosolic tyrosines,
followed by MS [92]. Independent peptide pull-downMS identiﬁed
56 proteins, including 10 unique proteins (9 SH2/PTB proteins),
most notably STAT5 as an EGFR interactor. EGFR and ErbB4 shared
diverse interaction partners whereas ErbB2 and ErbB3 preferably
bound Shc and PI3-kinases, respectively. Jones et al. performed a
SH2/PTB domain microarray with 33 tyrosine residues of ErbB
receptors [22]. This approach identiﬁed numerous known and pre-
viously undocumented SH2/PTB-pTyr interactions, including 54
involving EGFR, 59 involving ErbB2, 37 involving ErbB3, and 8
involving ErbB4. Binding proﬁles of ErbB receptor sites were dis-
tinct: EGFR and ErbB2 binding became more promiscuous at high
ligand concentration, while ErbB3 binding was independent of li-
gand concentration. A follow up study showed that the ErbB4
receptor displayed a more selective binding proﬁle than the other
receptors [93]. This observation appears to be inconsistent with
the promiscuous proﬁle of ErbB4 in Schulze’s pull-down data [92].
Reasons for this discrepancy are unknown, although the meth-
odologies used in these three studies were quite distinct. First, the
Table 2
ErbB4 pTyr site binding proteins. Four pYXN motifs of the ErbB4 cytosolic region were studied by pull-down MS and domain microarray. Identiﬁed binding
proteins for each site are compared with Scansite predictions.
ErbB4 site Sequence Pull down Microarray Scansite
Y1162 PMRDKPKQEpYLNPVEEN Grb2 Vav2; RASA1; Arg PLCg; Grb2; Abl
Y1188 DLQALDNPEpYHNASNGP Grb2; She She; Arg Grb2; She
Y1202 NGPPKAEDEpYVNEPLYL Grb2 Syk Grb2; PLCg
Y1208 EDEYVNEPLpYLNTFANT Grb2 – –
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direct and indirect binding partners of EGFR in vivo. Second, while
Schulze’s pTyr-peptide pull-down is a sensitive approach, some
tyrosines used in the study may not be phosphorylated in vivo.
Thus, observed binding may or may not be physiological. Third,
while the sensitivity of the domain microarray approach should
very high because domain–peptide interactions occur at ﬁxed con-
centrations in a buffered solution without any competition or
interference from other molecules, the activity of recombinant do-
main proteins can be lost in vitro due to misfolding, degradation,
etc., resulting in poor reporting of physiological binding. These
methodological differences should be taken into account in assay
design and data interpretation. Limitations of these methodologies
suggest that one approach is insufﬁcient to correctly identify all
physiological interactions. To illustrate this, we have summarized
observed interactions from two studies mentioned above and
Scansite predictions for four pYXN motifs of ErbB4 in Table 2.
Shc binding to pY1188 is shared among three and Grb2 is promi-
nently identiﬁed in pull-down. Further, microarray and Scansite
indicate that more potential binding partners may exist in vivo.
These differences may signify the complementarity of the three
orthogonal methodologies.
5.2. Proline rich sequence recognizing domains
Polyproline sequences are thought to provide a favorable do-
main–motif interface due to the stability of their helical conﬁrma-
tion, hydrophobicity, and presence on the surface of proteins
[94,95]. As a consequence, multiple domain families involved in
subcellular localization and the assembly of multiprotein com-
plexes recognize proline rich motifs [96]. SH3 domains were the
ﬁrst member of this group, discovered in 1988, followed by WW,
EVH, and GYF domains (Table 1) [97–100]. It is worth noting that
the ﬁrst demonstration of polyproline recognition came from an
early motif scanning experiment; a cDNA expression library was
screened using a GST-tagged Abl SH3 domain as bait. Subsequent
deletion analysis using the positive clones led to the ﬁnding [11].
The speciﬁcity of these domains to short proline-rich peptides is
generally modest, with afﬁnities in the low micromolar range (Ta-
ble 1). However biochemical and structural studies suggest greater
selectivity may be conferred by a larger binding surface [101,102].
Given the large number of proline-rich sequence recognizing do-
mains and the important role of selectivity in signaling (Table 1)
[1], one might ask: What portion of these domains are selective
or promiscuous? Additionally, do predicted peptide consensus
classes, usually deﬁned by in vitro screening, actually govern pro-
tein complexes in vivo? Several WW domainomics studies have
provided partial answers to these intriguing questions.
Hu et al. generated a peptide–domain interaction map with 65
human WW domains and 1930 proline-rich peptides using an ELI-
SA-type assay on a massive scale [74]. Interestingly, a number of
WW domain binding sites showed selectivity. Of the 1056 pro-
line-rich peptides which showed some binding, 33% bound to only
1–3 domains, 60% to 4–30 domains, and 7% to more than 30 do-
mains. On the other hand, relative afﬁnity comparisons based on
signal intensity classiﬁed only 3.7% of interactions as strong whilethe remainder were medium or weak. In another study, Pawson
and co-workers performed a pull-down experiment with a set of
10 WW domains, including all four in vitro deﬁned consensus sub-
classes and identiﬁed 148 proteins by MS [26]. Hierarchical clus-
tering segregated the 10 WW domains into three clusters based
on the subset of proteins they bound. All 148 binding proteins
were then categorized by the presence of previously deﬁned WW
subclass consensus motifs, e.g., PPXP, revealing good correlation
between domain and motif subclasses. For example, PPXY motifs
were preferentially enriched in a subgroup that contained WW do-
mains with PPXY ligand speciﬁcity. Hence this correlation suggests
consensus motifs identiﬁed in vitro indeed govern protein interac-
tions in vivo. Further, functional analysis of WW domain
pull-downs suggested that precipitated proteins represent physio-
logical complexes in vivo. Taken together, these WW domain
studies argue domainomics methods are sufﬁciently speciﬁc to
provide a bottom up understanding of in vivo domain-based
protein–protein interactions.
5.3. Phosphoserine/threonine recognizing domains
While it was surprising when dimeric 14-3-3 proteins were
found to be genuine phosphoserine/threonine recognition modules
[103], it quickly became apparent that other modular domains
such as, FHA, WW and BRCT also share this behavior (Table 1)
[104–106].
14-3-3 family proteins have attracted scientists’ attention be-
cause of their involvement in important cellular processes, such
as signal transduction, and in disease [107]. 14-3-3 domainomics
studies have been conducted for speciﬁcity mapping by peptide
screening [108,109], and protein identiﬁcation by pull-down MS
[110]. To date, several hundred interacting proteins have been re-
ported including Raf and BCR [99], however direct binding has yet
to be conﬁrmed for many of them [100]. One perplexing problem,
however, is that 14-3-3 interactomes produced by many studies
display remarkably little overlap (20–40%). This may be attributed
to differing experimental conditions such as enrichment methods,
cell type, in vivo vs. in vitro, direct vs. indirect binding, or type of
bait used [110–113].
Another plausible explanation is isoform dependence. 14-3-3
isoforms have been implicated to play unique roles in human dis-
ease, suggesting that each may bind a distinct set of ligands
[114,115]. Intriguingly, experimental data to date seem to be insuf-
ﬁcient to explain apparent isoform selectivity in vivo. All isoforms
share high afﬁnity motifs RSXpSXP and RXF/YXpSXP with some
variation [116], and a peptide scanning study failed to detect any
isoform-speciﬁc phosphopeptide binding [117]. Structural obser-
vations also demonstrated that the conformation of 14-3-3 hetero-
and homo-dimers were largely similar indicating their structural
rigidity [116]. Thus, it has been hypothesized that 14-3-3 dimers
act as rigid molecular scaffolds keeping an enzyme in its active
conformation through a bidentate interaction [118]. Nevertheless,
isoform speciﬁc ligands and minor conformational variability and
ﬂexibility have been reported [116,119]. Therefore, it is likely 14-
3-3 proteins largely share their ligands to exert broad regulatory
functions, while playing selective roles by interacting with a few
2592 J.A. Jadwin et al. / FEBS Letters 586 (2012) 2586–2596isoform-speciﬁc ligands. To address this issue, multiplex scanning
domainomics, comparing all isoforms in equivalent conditions,
would be informative.
BRCT, FHA, and 14-3-3 work cooperatively in the DNA damage
response. DNA strand breaks activate the recruitment of serine/
threonine kinases to the damage site, where they phosphorylate
DNA repair proteins, transcription factors, protein kinases, and
scaffolds [120,121]. Phosphorylation signals are then ‘‘read’’ by
proteins containing BRCT-1, FHA, and 14-3-3 domains. This process
is organized as a hierarchy of domain–phosphosite binding inter-
actions where speciﬁcity of kinases and domains are tightly regu-
lated to prevent molecular signals from getting crossed [122]. For
example, ATM kinase preferentially phosphorylates serine sites
that are favored by MDC1 BRCT domains, while Chk kinase phos-
phorylates the motif recognized by 14-3-3 [123,124]. In addition,
other PTMs such as ubiquitination and methylation also play roles
in the DNA damage response [125].
The link between BRCT domains and pS/pT-motifs was initially
illuminated by a well-designed multiplex scanning study [106]. To
identify novel phosphorylation-dependent domains involved in
the DNA damage response, Manke et al. performed a pull-down as-
say against a cDNA expression library using an oriented phospho-
peptide library mimicking ATM kinase substrates as bait. Proteins
that bound in a phosphorylation-dependent manner were visual-
ized by gel electrophoresis, which resulted in identiﬁcation of the
multi-BRCT domain-containing protein PTIP. Interestingly, they
found that C-terminal tandem BRCT domains of PTIP function as
a single module for phospho-speciﬁc binding. This ‘‘library to li-
brary pull-down’’ method is advantageous in that identiﬁcation
of PTM-recognizing domains is feasible without specifying a motif
sequence and types of domains. Recently, this method has been
combined with SILAC-MS technology leading to identiﬁcation of
a novel pTyr-binding module [89].
Highly dynamic and selective interactions at domain-PTM sites
in the DNA damage response raise many questions: How many
tandem BRCT domains are phosphorylation-dependent? How
many domains are highly selective or promiscuous? Why are BRCT
domains generally conﬁned to DNA damage response signaling?
While some studies have begun to address these questions [126],
systematic domain binding analyses should provide more compre-
hensive answers.
5.4. Carboxyl terminus binding/PDZ domains
PDZ (PSD-95, DLG-4, ZO-1) domains are carboxyl terminal bind-
ing modules found in proteins generally considered to play a role
in maintenance of cell polarity and adhesion [127]. Domains were
initially divided into two major classes based on oriented peptide
screening [128]. A third outlier class has also been proposed based
on its lack of consensus with groups I and II [129]. Recently two
large-scale studies have been undertaken to more explicitly deﬁne
the speciﬁcity space of PDZ domains. Tonikian et al. screened a
phage display library harboring 10 billion random C-terminal pep-
tides against 82 PDZ domains from human and Caenorhabditis ele-
gans, revealing that greater than 90% of PDZ domains ﬁt into one of
sixteen classes [21]. Stifﬂer et al. performed a domain microarray
screen of 157 mouse PDZ domains probed with 217 C-terminal
peptides. Surprisingly, they found that PDZ domains do not fall into
discrete speciﬁcity classes; rather they lie on a continuum, evenly
dispersed across the speciﬁcity space [2]. These data suggest that
simpliﬁed classes based on consensus motifs are not suitable to
precisely predict novel PDZ domain–ligand interactions.
Several groups have applied these binding datasets to develop
prediction models. Using the microarray data, Chen et al. devel-
oped a modiﬁed PSSM that integrated domain/motif structural
contact map information and was capable of predicting novelPDZ domain interactions across multiple species [31]. The sensitiv-
ity of this model was conﬁrmed by another group using an inde-
pendent human data set, although the false positive rate was
shown to be higher than originally described [32]. Hui et al. incor-
porated Chen’s contact map information and trained a machine
learning method using both phage and microarray data [130]. This
approach signiﬁcantly reduced the false positive rate. Instead of
structural information, Li et al. used evolutionary relatedness of
domain sequences and a PSSM to compare different domains,
which resulted in increased predictive accuracy [30]. The model,
referred to as DomPep, is publicly available online. Together, multi-
ple efforts have been made to improve PDZ interaction prediction
models. It is not possible to rank different prediction tools without
a comparable value such as sensitivity or speciﬁcity, although we
observed that ROC area under the curves for these models gener-
ally fell between 0.75 and 0.9, indicating good prediction accuracy.
However, the obvious problem is that all models have been trained
using two limited data sets based on PDZ domains from only three
species. Because models are greatly affected by their training data
set, broad validated experimental data is a requisite for further
development. In addition, integration of protein expression and
PTM data [131] could also provide more meaningful predictions
of protein–protein interactions in vivo.
5.5. Methyllysine binding domains
PHD (Plant Homeodomain) ﬁngers and Royal Family domains
(Chromo, Tudor, MBT, and PWWP) recognize methyllysine and
methylarginine on histone tails in the context of ﬂanking residues
[132]. These domains are thought to act as ‘‘readers’’ of the histone
code which translate histone PTMs into biological outcomes in a
process that in some ways parallels reading of tyrosine phosphor-
ylation by SH2 domains [133,134].
Intriguingly, over 392 proteins have been shown to contain at
least one of these ﬁve domain families, yet only 10 methylated
residues have been identiﬁed on human histones [135,136]. This
raises the question: How do so many domains speciﬁcally interact
with so few ligands? Several domainomics studies have provided
some clues. A domain scanning approach employing a microarray
of 109 PHD ﬁngers and Royal Family domains, probed with histone
tail peptides identiﬁed Tudor and MBT domains whose binding is
dependent on the degree of lysine methylation (mono, di, tri)
[20]. Further, peptide pull-down experiments employing a set of
PHD ﬁnger, Tudor and WD40 domains showed that binding to
methyllysine could be signiﬁcantly affected by nearby arginine
methylation [137]. To test the effect of other PTMs, Garkse et al.
performed a motif scanning assay in which a histone-3 N-terminal
peptide bead library containing over 5000 randomized PTM combi-
nationswas probedwith ﬁve PHDﬁngers [13]. The screen identiﬁed
a number of PTMs, including arginine methylation and threonine
phosphorylation, which modulated PHD-methyllysine binding via
switch (binary binding) and rheostat-like (variable binding) mech-
anisms. Subsequent SILAC-MS (domain scanning) and peptide array
(motif scanning) experiments added support to the importance of
phosphorylation in methyllysine binding [138,139]. Taken to-
gether, these results suggest combinatorial PTMs provide speciﬁc-
ity for domain binding to histone tails, adding credence to the
theory that neighboring PTMs confer widespread regulation of his-
tone tail effector binding [140]. A complete understanding of this
mechanism will require further studies including a greater number
of methyllysine binding domains.
5.6. b-Propeller family
WD40 repeats are one of the most abundant domain families
found in eukaryotic proteomes (Table 1). They rank as one of the
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are found in proteins which play roles in a diverse set of biological
functions, including signal transduction and vesicular trafﬁcking
[142,143]. It is hypothesized that WD40 domains act as a scaffolds
for multiprotein complexes. These domains differ from ‘‘classical’’
modular protein domains in multiple ways: Typically WD40 re-
peats fold into a non-catalytic, seven blade b-propeller that func-
tions as an independent module. These propellers share little
sequence conservation, and studies have shown they have PTM-
dependent (e.g., phosphorylation, ubiquitination, and methylation)
and independent substrates [144,145]. In this sense, WD40 propel-
lers behave in a similar manner as antibodies, providing a frame-
work on which speciﬁcity for different ligands can be built.
The unique features of WD repeats could impede application of
conventional domainomics. For example, motif scanning, to deﬁne
binding speciﬁcity for poorly understood WD40 proteins, would
require an enormous peptide library containing unrelated motifs
and different types of PTMs. Further, recombinant WD propeller
proteins tend to be insoluble proving a hurdle for in vitro studies
[146]. As a result, a systematic inspection of WD40 ligand selectiv-
ity has yet to be undertaken to date. Nevertheless, it has been
shown that SPOT array scanning was able to deﬁne the consensus
motif of the Cdc4 WD40 propeller, suggesting a multi-domain
study is feasible. In addition, their deep involvement in the human
interactome and multiple PMT-dependency suggests a possible
role as signaling gatekeepers. For instance, there is a switch-like
interaction betweenWD40 repeats of Cdc4 andmultiple phosphor-
ylation sites of Sic1; only when all six sites are phosphorylated, can
the WD40 repeats bind Sic1 leading to cell-cycle progression [147].
Thus, it would be interesting to exploit WD40 repeats as molecular
probes to distinguish ﬂuctuations in cellular signaling pathways,
e.g., as biosensors for a multiply phosphorylated site.6. Perspectives
6.1. Domainomics-reducing the complexity
The major premise of domainomics is that in vivo protein net-
works are generally governed by interactions between modular
protein domains and short peptide motifs, and that these interac-
tions are generally reproducible in an in vitro binding assay. Unfor-
tunately, some information is lost at the expense of the
convenience provided by this overly simpliﬁed view. First, non-do-
main-dependent binding that relies on the reciprocal large surface
interactions between proteins will be missed [148]. Second, coop-
erative interactions involving multiple domains might also be
missed [149]. Third, transient enzyme–substrate interactions
may not be captured. Thus domainomics does not provide a com-
plete picture of regulatory protein networks. Nevertheless, do-
mains and motifs are valuable tools for surveying speciﬁc
domain–motif interactions, and thus widely used in motif and do-
main scanning, as outlined above.
We believe, however, the power of domainomics can be fully ex-
erted in multiplex scanning formats, especially when many do-
mains are employed. By incorporating all functionally similar
domains into a high-throughput system, it is possible to dissect
individual layers of a complex full-length protein interaction net-
work. For example, the SH3/WW domain–ligand map is a subset
of the interactome involving only proline-rich sequences [43,150].
Such a sub-networkmap is not only useful to overview the distribu-
tion of binding speciﬁcity and promiscuity, but also to predict ef-
fects caused by interruption or overexpression at a particular
interaction node and in rewiring networks [151,152]. Likewise,
functional layers based on phosphotyrosine, phosphoserine, and
methyllysine dependent domains should provide distinct interac-tion maps. Usefulness of this approach is visible even when using
a subset of domains or motifs. For example a SH2 and PTB domain
macroarray provided a pTyr-dependent effector map for ErbB/EGFR
family members, revealing a qualitative difference among them
[22]. Another study compared interaction proﬁles of selected WW
domains and suggested a connection may exist between binding
motifs and speciﬁc subcellular systems [26]. Taken together, multi-
plex scanning domainomics offers a unique tool to dissect interact-
omes in a way not obtainable through non-domain proteomics.
6.2. Genome-wide domainomics
Given the potential of domainomics and the availability of ad-
vanced technologies and bioinformatics, is it now possible to con-
struct many different interactomes based on modular protein
domains and their binding proteins? Unfortunately, because the
domainomics toolbox is insufﬁcient, the answer is No. Publicly
available complete domain libraries are limited to only a few do-
mains, e.g., SH2 and SH3, precluding the construction of compre-
hensive domain-interaction maps. There are, however,
independent efforts to create such libraries and interaction maps
for a number of domains [2,43,74]. In the long term though, redun-
dant collection of clones by individual research groups is highly
inefﬁcient. Ideally, the modular domain research community
should work together to bank domain constructs.
Along with modular interaction-dedicated domains, enzyme
catalytic domains may be a potential addition to the toolbox.
PTM-dependent protein interactions are governed by the speciﬁc-
ities of both binding domains (readers, e.g., SH2s) and enzymes
(writers and erasers, e.g., tyrosine kinases and phosphatases)
[153]. Although enzymes bind substrates transiently, making them
inappropriate for use as afﬁnity reagents, stabilization of binding
by mutagenesis or cross-linking is feasible at least in part
[154,155]. These enzymes, as well as modiﬁed interaction domains
[155,156] and domain-speciﬁc antibodies [157,158], may strength-
en domainomics by revealing further functional layers of protein–
protein networks.
7. Concluding remarks
In this review, we highlighted a portion of proteomics (domai-
nomics) focusing on how modular protein interacting domains
are popularly used as a means to address speciﬁc scientiﬁc ques-
tions. Methods involving domains and their motifs are increasingly
playing a role in the proteomics era, powered by the availability of
genome data, domain prediction tools, and high-throughput tech-
nologies. Accumulation of domain–motif binding data will ulti-
mately lead to a domain-based interactome, providing insights
into the underlying structure of protein networks and the selectiv-
ity and plasticity of signal transduction.
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